The ability of vertebrates to detect and avoid damaging extremes of temperature depends on activation of ion channels belonging to the thermo-TRP family. Injury or inflammation causes the release of inflammatory mediators which lower the threshold for detection of painful levels of heat, a process known as heat hyperalgesia. These inflammatory mediators act by at least three distinct intracellular signaling pathways. Here, we show that modulation of the sensitivity of the heat-activated ion channel TRPV1 by the protein kinases PKA and PKC and by the phosphatase calcineurin depends on the formation of a signaling complex between these enzymes, the scaffolding protein AKAP79/150 and TRPV1. We identify a critical region in the TRPV1 C-terminal which mediates binding of AKAP79/150. If binding is prevented, then sensitization by both bradykinin and PGE 2 is abrogated. AKAP79/150 is therefore a final common element in heat hyperalgesia, on which the effects of multiple proinflammatory mediators converge.
INTRODUCTION
Animals detect thermal stimuli via the activation of primary sensory nerve terminals responding to a range of temperatures from noxious cold, through the innocuous range, and extending to damaging extremes of heat (Darian-Smith, 1984; Perl, 1984; Lumpkin and Caterina, 2007) . Thermal stimuli activate inward membrane currents in temperature-sensitive neurons (Cesare and McNaughton, 1996; Reid and Flonta, 2001) , and they do so by the direct activation of temperature-sensitive ion channels belonging to the thermo-TRP family (Jordt et al., 2003; Venkatachalam and Montell, 2007; Nilius et al., 2007) . The best-studied thermo-TRPs are as follows: TRPV1, which is activated by noxious temperatures above 43 C (Caterina et al., 1997) ; TRPV2, activated by higher temperatures, above 52 C (Caterina et al., 1999) ; TRPV3 and TRPV4, activated in the range of innocuous warmth, c. 35 C-37 C (Smith et al., 2002; Xu et al., 2002; Guler et al., 2002; Watanabe et al., 2002) ; TRPM8, activated by cooling below c. 30
C (McKemy et al., 2002) ; and TRPA1, which may be activated by more extreme cooling (Story et al., 2003) , though other recent studies have failed to confirm the activation of this ion channel by cold (Bautista et al., 2006; Zurborg et al., 2007) . The temperature thresholds of thermally activated ion channels are modulated by a range of extracellular factors (Huang et al., 2006) . The temperature threshold of TRPV1, the best-studied thermo-TRP channel, is lowered by proinflammatory mediators such as bradykinin, prostaglandin E 2 (PGE 2 ), and nerve growth factor (NGF). The lowering of the TRPV1 threshold is critical for heat hyperalgesia, the process by which the threshold for heat pain is lowered following inflammation or injury, because heat hyperalgesia is ablated when TRPV1 is genetically deleted (Davis et al., 2000; Caterina et al., 2000) .
Three pathways are known to lead to sensitization of TRPV1. The activation of the G q -coupled B1 and B2 receptors by bradykinin lowers the temperature threshold of TRPV1 by promoting phosphorylation by PKC3 (Cesare and McNaughton, 1996; Cesare et al., 1999; Numazaki et al., 2002; Bhave et al., 2003) . An alternative possibility, that metabolism of PIP 2 by PLCb may release TRPV1 from PIP 2 -mediated inhibition (Chuang et al., 2001) , is not supported by more recent evidence showing that PIP 2 in fact activates rather than inhibiting TRPV1 (Stein et al., 2006; Lishko et al., 2007) . In sensory neurons, PGE 2 activates the EP 4 receptor, which is G s coupled and causes sensitization by promoting PKA-dependent phosphorylation of TRPV1 (Bhave et al., 2002; Distler et al., 2003) . In a third pathway leading to sensitization of TRPV1, NGF potentiates TRPV1 by activating PI3 kinase and the tyrosine kinase Src, leading to phosphorylation of TRPV1 at Y200 and to promotion of trafficking of TRPV1 to the neuronal cell membrane (Zhang et al., 2005; Stein et al., 2006) . A proposal that NGF sensitizes TRPV1 by activating PLCg and thus reducing levels of PIP 2 (Chuang et al., 2001; Prescott and Julius, 2003) is not supported by more recent evidence (Zhang et al., 2005) .
The speed and specificity of the action of kinases is in many cases enhanced by the use of scaffolding proteins which preassemble the kinases into signaling complexes with their substrates. The AKAP (A kinase anchoring protein) family of scaffolding proteins were originally named for their ability to target PKA to appropriate substrates but are now known to assemble a wide range of kinases and phosphatases into signaling complexes with appropriate targets (Leiser et al., 1986; Bregman et al., 1989 ; reviewed by Smith et al., 2006) . AKAP79/150 targets PKA, PKC, and the Ca-dependent phosphatase calcineurin to appropriate substrates (Coghlan et al., 1995; Klauck et al., 1996) . AKAP79 is the human homolog, while AKAP150, the rodent homolog, seems to be similar in function to AKAP79 but contains an additional large central domain.
A number of ion channels are subject to modulation by AKAPs, including glutamate receptors, calcium channels, and M-type potassium channels (Gao et al., 1997; Colledge et al., 2000; Altier et al., 2002; Hoshi et al., 2003 Hoshi et al., , 2005 Sandoz et al., 2006; Oliveria et al., 2007; Lu et al., 2007; Chai et al., 2007; Navedo et al., 2008 ). An AKAP may be involved in the (A) TRPV1 (left) and AKAP150 (center) coexpress in small (<25 mm dia) rat DRG neurons (merged image at right). The majority of TRPV1 is present in subcellular vesicles (Zhang et al., 2005) . 91.1% ± 1.7% of TRPV1-positive neurons express AKAP150 (n = 352; values given as mean ± SEM in this and all subsequent instances). Scale bar 10 mm. (B) Immunoprecipitating TRPV1 from rat DRG neurons coimmunoprecipitates AKAP150 (upper blot, right lane). A control experiment using rat IgG does not immunoprecipitate either TRPV1 or AKAP150. (C) AKAP150 can be downregulated in rat DRG neurons by the use of an siRNA against AKAP150. The vector chosen for the siRNA expression also coexpressed GFP so that successfully transfected neurons could be identified (left column). A scrambled siRNA had no effect on AKAP150 levels in successfully transfected neurons (top), but the siRNA against AKAP150 downregulated expression (middle; mean 12.1% ± 1.9% of untransfected neurons in same images, n = 6). Lower pair of images compares the effect of siRNA in adjacent transfected and untransfected neurons. Scale bar 20 mm. (D) Similar experiment in which AKAP79 in HEK293 cells was downregulated to a mean value of 15.9% ± 2.6% of control (n = 22) by the use of an siRNA against AKAP79. AKAP79 and siRNA against AKAP79 were simultaneously coexpressed. Scale bar 10 mm. (E) Western blot showing downregulation of AKAP79 in HEK293 cells by siRNA and lack of effect of scrambled siRNA. Mean downregulation was to 30.4% ± 2.5% of control (n = 3), but note that this includes some untransfected cells (c. 20% of total). Bottom image shows same blot stripped and reprobed for b tubulin to check similar loading in each lane. modulation of TRPV1 by PKA (Rathee et al., 2002; Distler et al., 2003) , but neither the AKAP family member involved nor its binding site on TRPV1 have been identified, and the possibility that other kinases such as PKC and Src may also be assembled into a functional signaling complex important in the regulation of TRPV1 has not been explored. These questions are addressed in the present paper.
RESULTS

Coexpression of AKAP79/150 and TRPV1 in Sensory Neurons
Several AKAPs are expressed in sensory neurons, among them AKAP79/150 (Rathee et al., 2002) . Figure 1A shows that the vast majority of rat DRG neurons which express TRPV1 (left panel) also express AKAP150 (center panel and merged image in right panel). We found that 91.1% ± 1.7% of neurons expressing TRPV1 also expressed AKAP150 (mean ± SEM; n = 352). Evidence for a physical association between the two in sensory neurons was obtained in coimmunoprecipitation experiments in which pull-down of TRPV1, using an antibody raised to the TRPV1 N-terminal domain, also brought down AKAP150 ( Figure 1B) .
In later experiments in this study it was important to be able to manipulate endogenous AKAP79/150 levels in both DRG neurons and in a HEK293 expression system. We constructed an siRNA against AKAP150 and AKAP79, as used by Hoshi et al. (2005) but in a vector which coexpresses GFP to enable identification of successfully transfected cells. The siRNA against AKAP150 reduced expression levels in transfected rat DRG neurons to 12.1% ± 1.9% of control ( Figure 1C ; n = 6), and the siRNA against AKAP79 reduced expression in HEK293 cells to 15.9% ± 2.6% of control ( Figure 1D ; n = 22). A similar but lesser downregulation was seen in Western blots of HEK293 cell protein ( Figure 1E ; 30.4% ± 2.5% of control, n = 3), a difference which is expected because not all cells are transfected. In all cases a scrambled siRNA with the same base composition was completely ineffective ( Figures 1C-1E ).
Binding of AKAP79 to Thermo-TRPs
The experiments in Figure 2 show that AKAP79 expressed in HEK293 cells binds to several members of the thermo-TRP family of ion channels. AKAP79 expressed in HEK293 cells coimmunoprecipitates with several thermo-TRPs (Figures 2A and 2B ), particularly with TRPV1 and TRPV4, and to a lesser extent TRPM8 and TRPA1. Endogenous AKAP79 can also coimmunoprecipitate lesser amounts of TRPV1 ( Figure 2B , top left panel). Figure 2C shows that the binding between TRPV1 and AKAP79 does not depend on the use of the V5 tag attached to the C-terminal as it is also observed when an antibody raised to the N-terminal TRPV1 domain is used.
We next localized the TRPV1 binding site for AKAP79 by constructing GST-coupled fragments of the four intracellular domains of TRPV1, expressed in bacteria, and exploring binding to AKAP79 in vitro. The major binding domain is in the C-terminal portion of TRPV1 ( Figure 2D ), with only weak binding observed to the large N-terminal domain and no detectable binding to either of the intracellular loops. When the GST-coupled C-terminal domain was progressively truncated, there was an increase in binding on removal of the region between amino acids 759 and 777, probably because of removal of an inhibitory region, but more significantly there was a substantial loss of binding on removal of amino acids 736 to 749 ( Figure 2E , left panel; note that all residue numbering is for hTRPV1). Deletion of just this region caused a major reduction in binding, while other nearby deletions were much less effective ( Figure 2E , right panel). We repeated this deletion in intact TRPV1, expressed in HEK293 cells, and found that removal of this region also caused a substantial reduction in the binding of AKAP79 to intact TRPV1 (see Figure S1A available online). We next constructed a 14 aa peptide, identical to this binding domain, which should be able to compete for the site on AKAP79 to which TRPV1 binds. At a concentration of 200 mM this peptide largely prevented binding of AKAP79 to the GSTcoupled C-terminal fragment of TRPV1, while a scrambled peptide of the same composition was ineffective ( Figure 2F ). The peptide was also highly effective in displacing AKAP79 from binding to intact TRPV1 ( Figure 2G ).
AKAP79/150 Promotes Activation of TRPV1
We found that expression of AKAP79 enhanced the sensitivity of TRPV1 to capsaicin even in the absence of overt activation of PKC or PKA by proinflammatory mediators ( Figure 3A , compare red points and red curve with black points and black curve). Conversely, expression of AKAP79 with the PKC binding site deleted (Hoshi et al., 2005) reduced the sensitivity of TRPV1 to activation by capsaicin (green points and curve). The fact that AKAP79 can enhance sensitivity, while deletion of the PKC binding site on AKAP79 has a dominant-negative effect, shows that phosphorylation by PKC is important in modulating sensitivity of TRPV1 even in the resting cell. The results also show that endogenous AKAP79 does not saturate its binding sites on TRPV1, because overexpression of AKAP79 has an effect greater than that of endogenous AKAP79.
Deletion of the PKA binding site had a smaller effect than deletion of the PKC site (gray squares), showing that phosphorylation by constitutively active PKA is less important than PKC in the resting cell. The effect of expression of an AKAP79 with the calcineurin (PP2B) binding site deleted was indistinguishable from that of wild-type AKAP79 (blue points), suggesting that calcineurin bound to AKAP79 makes little contribution to dephosphorylating TRPV1 at resting levels of calcium.
TRPV1 ion channels can be opened even in the absence of agonist by strong membrane depolarization (Voets et al., 2004) . Activation of PKC potentiates this process by enabling opening of TRPV1 at lower membrane potentials (Matta and Ahern, 2007) , and our demonstration that AKAP79 is involved in potentiation of TRPV1 by PKC suggests that it will have a similar effect. Figure 3B shows that activating PKC or overexpressing AKAP79 both have similar effects in potentiating the opening of TRPV1 by membrane depolarization, and moreover that the actions are to some extent additive. Figures 3C and 3D demonstrate that overexpression of AKAP79 shifts the voltage activation curve to less depolarized potentials by 54 mV, and that subsequent full activation of PKC causes an additional 32 mV negative shift. In summary, the experiments in Figure 3 show that expression of AKAP79 promotes activation of TRPV1 by both capsaicin and membrane potential, and moreover that this action depends mainly on the binding of PKC to AKAP79.
AKAP79/150 Is Essential for Sensitization of TRPV1 via PKC and PKA Pathways
We next investigated whether AKAP79/150 mediates the sensitization of TRPV1 caused by proinflammatory mediators. For these experiments, we used a low dose of capsaicin as a convenient activator of TRPV1, because the sensitivity of TRPV1 to heat, capsaicin, low pH, and a range of other activators is known to be enhanced in a similar way by proinflammatory mediators (Vellani et al., 2001) .
In rat sensory neurons, bradykinin caused a substantial enhancement of the inward current mediated by TRPV1 ( Figure 4A ), a process which has been shown to be due to phosphorylation of serines 502 and 801 by PKC3 (Cesare and McNaughton, 1996; Cesare et al., 1999; Numazaki et al., 2002; Bhave et al., 2003) . Incorporation of the 14 aa peptide which prevents binding of AKAP150 to TRPV1 completely inhibited sensitization by Bk, while the scrambled peptide was ineffective ( Figures 4A and 4B ). An alternative way of demonstrating an involvement of AKAP150 is to downregulate endogenous expression using siRNA. Figures 4A and 4B show that removal of AKAP150 in this way almost completely inhibited the action of Bk in sensory neurons, while a scrambled siRNA was ineffective. Finally, simultaneously transfecting with AKAP79, which is insensitive to the siRNA against AKAP150 (Hoshi et al., 2005) , rescued the sensitization by BK, and in fact the overexpression of AKAP79 causes an enhanced level of sensitization (final bar, Figure 4B ). (A) Members of the thermo-TRP family of ion channels coimmunoprecipitate AKAP79. TRP proteins were immunoprecipitated with an antibody to a V5 tag fused to the TRP C termini, and association of cotransfected AKAP79 was probed as shown in top blot. Expression levels of TRP proteins were similar in all cases (middle blot, which is top blot stripped and reprobed), apart from the first lane in which no TRP was transfected. Note the double principal bands for most TRPs, due to the presence of glycosylated (mature) and nonglycosylated (immature) protein (Jahnel et al., 2001 ). The V5 antibody does not crossreact with any endogenous HEK293 cell proteins (see left lane, in which no TRP was transfected), and fainter bands of lower M.Wt. are due to the presence of truncated versions of the V5-tagged TRPs. Lower blot of total cell lysate (TCL) shows that AKAP79 expression was similar in all lanes. (D) GST-coupled fragments of the hTRPV1 N-terminal (residues 1-433), intracellular loop 1 (498-513), intracellular loop 2 (557-579), and C-terminal (681-839) were expressed in E. coli, purified, and tested for their ability to coIP AKAP79. Note that all residue numbering is for the hTRPV1 used in these experiments. Bottom image, from an independent run, shows Coomassie stain of similar gel to demonstrate that expression levels of GST-coupled constructs were similar in all lanes. Principal band in each lane is the GST-coupled construct; other bands are bacterial proteins incompletely removed during purification. (E) GST-coupled fragments of the hTRPV1 C-terminal domain (681-839) were truncated as shown (left) or internal regions were deleted (right) and were examined for ability to coimmunoprecipitate AKAP79. Bottom image at left shows GST-coupled fragments stained with Coomassie in an independent run; bottom image at right shows blot above stripped and reprobed for GST to demonstrate similar loading in all lanes. (F) A 14 aa peptide of sequence KDDYRWCFRVDEVN, corresponding to residues 736-749 of hTRPV1, displaces binding between AKAP79 and TRPV1 GSTcoupled C-terminal. A peptide with the same composition but with scrambled sequence VCEYDVFDRNDKWR is ineffective. (G) Inhibitory peptide (see [F] ) displaces binding between intact TRPV1 and AKAP79, while scrambled peptide is ineffective. Peptide added at stated final concentrations directly to lysate of HEK293 cells transfected with TRPV1 and AKAP79.
Bradykinin also caused a substantial sensitization of TRPV1 in HEK293 cells transfected with the G q -coupled B2 receptor ( Figure 4C ). Sensitization was abolished by deletion of the PKC binding site on AKAP79, by downregulation of endogenous AKAP79 with siRNA, or by mutation of the S502 and S801 sites on TRPV1, which are known targets for phosphorylation by PKC (Numazaki et al., 2002; Bhave et al., 2003; see Figure 4D ). Deletion of the PKA binding site, however, had a lesser effect than deletion of the PKC site ( Figure 2C ), as expected because PKC is the main kinase activated by bradykinin. The experiments in Figure 4 show that simple activation of PKC by a proinflammatory mediator such as bradykinin is insufficient to cause sensitization of TRPV1. Formation of a scaffolding complex between TRPV1, AKAP79, and PKC is an essential prerequisite for PKC to sensitize TRPV1.
A second important proinflammatory mediator is the prostaglandin PGE 2 , which sensitizes TRPV1 in sensory neurons via both the G q -coupled EP 1 receptor and the G s -coupled EP 4 receptor (Lopshire and Nicol, 1998; Southall and Vasko, 2001; Bhave et al., 2002; Moriyama et al., 2005; Lin et al., 2006) . We found that application of PGE 2 to isolated rat sensory neurons caused a substantial sensitization, and as was the case with Bk, sensitization by PGE 2 was completely ablated by inclusion of the 14 aa peptide which blocks the AKAP79/150-TRPV1 interaction ( Figures 5A and 5B ). Downregulating endogenous AKAP150 by the use of siRNA had a similar inhibitory effect, and transfection of AKAP79 rescued the sensitization by PGE 2 . Interestingly, overexpression of AKAP79 did not produce a level of sensitization above that in untransfected neurons, in contrast to the enhanced sensitization seen with Bk. This difference is discussed further below.
In HEK293 cells coexpressing TRPV1 and the G q -coupled EP 1 receptor, application of PGE 2 caused significant sensitization ( Figure 5C , and see example traces in Figure S2A ). Overexpression of AKAP79 enhanced sensitization ( Figure 5C, bar 3) , which we attribute to a greater availability of the PKC binding site, an explanation which is reinforced by the similar enhancement observed when AKAP79 with the PKA site deleted was expressed ( Figure 5C, bar 4) . Sensitization was abolished, however, by expression of AKAP79 with the PKC site deleted, or by downregulation of endogenous AKAP79 by the use of siRNA ( Figure 5C , bars 5 and 6). These results show that sensitization of TRPV1 via the EP 1 receptor is completely dependent on the presence of AKAP79 containing a PKC binding site.
The results above show that PKC is able to phosphorylate TRPV1 only when AKAP79/150 is available to position the kinase appropriately. We also demonstrated this directly by the use of a phosphoserine antibody ( Figure S1B ). Serine phosphorylation was enhanced when PKC was activated with PMA, but when endogenous AKAP79 was eliminated by transfection of siRNA, the effect of PKC activation was abolished.
In HEK293 cells transfected with the G s -coupled EP 4 receptor, we found that sensitization was abolished by deletion of the PKA binding site on AKAP79 or by downregulation of endogenous AKAP79 by the use of siRNA, while deletion of the PKC site was without significant effect ( Figure 5D , and see example traces in Figure S2B ). These results show that sensitization via the EP 4 receptor depends on the presence of AKAP79 containing a functional PKA binding site.
An interesting difference between Figures 5C and 5D , which is also mirrored in the experiments on DRG neurons in Figures 4B and 5B, is that sensitization via the PKC pathway is enhanced when AKAP79/150 is overexpressed, but sensitization via the PKA pathway is already maximal with endogenous levels of AKAP79/150. Thus, endogenous levels of AKAP79/150 are not adequate to ensure full phosphorylation of TRPV1 when PKC is activated, and phosphorylation is boosted by transfection of further AKAP79/150, while endogenous levels of AKAP79/150 are adequate to ensure maximal phosphorylation of TRPV1 following activation of PKA. NGF sensitizes TRPV1 mainly by causing increased trafficking to the surface membrane via a pathway involving the tyrosine kinase Src (Zhang et al., 2005) . Does this pathway also depend on AKAP79/150? Figure 6A shows that NGF enhanced the membrane current activated by a near-saturating concentration of (A) Whole-cell voltage clamp experiments on small (<25 mm dia) rat DRG neurons. From top: bradykinin causes potent sensitization of inward current activated by a subsaturating pulse of capsaicin (100 nM, 5 s); inclusion of blocking peptide (200 mM) in the patch clamp pipette abolished sensitization; downregulation of AKAP150 by the use of siRNA largely abolished sensitization; sensitization was rescued by cotransfection of AKAP79, which is insensitive to the siRNA against AKAP150. These experiments were conducted in the presence of 1.8 mM external [Ca 2+ ], so substantial desensitization is observed in response to successive applications of capsaicin following application of Bk. Note that almost all TRPV1-positive neurons also expressed B2 receptors for Bk, as shown from the observation that >90% of naive neurons responding to capsaicin showed an enhancement of response following exposure to Bk. The suppression of sensitization by the inhibitory peptide or siRNA cannot therefore be attributed to chance selection of neurons not expressing receptors for Bk. (B) Collected results of experiments similar to those in (A). Bars show maximum amplitude of first response following application of Bk relative to last response before application. Bradykinin caused sensitization (bar 2; *, p < 0.05 compared to control, n = 19). Inclusion of peptide abolished sensitization (bar 3; ###, p < 0.001 compared to bar 2, n = 23). Scrambled peptide was ineffective in reversing sensitization by bradykinin (bar 4; *, p < 0.05 compared to control, n = 13). siRNA against AKAP150 largely abolished sensitization (bar 5; #, p < 0.05 compared to bar 2, n = 15), but this effect was not seen with scrambled siRNA (bar 6; *, p < 0.05 compared to control, n = 20). Abolition of sensitization following transfection with siRNA could be rescued by cotransfection of AKAP79, which is insensitive to the siRNA against AKAP150 (bar 7; ##, p < 0.01 compared to bar 2, n = 22). (C) Whole-cell voltage-clamp experiments on HEK293 cells transfected with TRPV1 and bradykinin B2 receptor. Bradykinin (1 mM) caused potent sensitization of the inward current activated by a subsaturating pulse of capsaicin (20 nM, 5 s). Sensitization was abolished by cotransfection of AKAP79 with the PKC binding site deleted, which has a dominant-negative effect, or by downregulation of endogenous AKAP79 expression with siRNA. Note that these experiments were conducted in the absence of external Ca
2+
, which explains why desensitization is absent. (D) Collected results of experiments similar to those in (C). Bradykinin caused potent sensitization (bar 2; ***, p < 0.001 compared to control, n = 25). Mutation of either or both target phosphorylation sites S502 and S801 to alanine largely abolished sensitization (bars 3-5, #, p < 0.05 and ##, p < 0.01 with respect to bar 2; n = 5, 8, and 12). Overexpressing AKAP79 causes enhanced sensitization (bar 6; #, p < 0.05 compared to bar 2, n = 16). Deleting the PKC binding site on AKAP79 largely abolishes sensitization (bar 7; ##, p < 0.01 compared to bar 2, n = 23). Deleting the PKA binding site is less effective (bar 8; not significant compared to bar 2, n = 10). Sensitization is abolished by downregulating expression of AKAP79 by the use of siRNA (bar 9; ###, p < 0.001 compared to bar 2, n = 17).
capsaicin, in agreement with previous studies (Zhang et al., 2005; Stein et al., 2006) . This effect is not, however, reduced by inclusion of the AKAP-TRPV1-blocking peptide in the pipette. We conclude that Src potentiates membrane trafficking of TRPV1 via an AKAP79/150-independent mechanism.
Involvement of AKAP79/150 in Desensitization AKAP79/150 contains a binding site for the calcium-dependent phosphatase calcineurin (PP2B) (Coghlan et al., 1995; Klauck et al., 1996) , suggesting that AKAP79/150 could play a role in desensitization of TRPV1, which is partly mediated by calcineurin (Docherty et al., 1996; Koplas et al., 1997; Vellani et al., 2001) . In Figure 6C , we investigated desensitization by applying a near-saturating conditioning dose of capsaicin, which evoked a large inward current and caused strong desensitization of the current evoked by a second capsaicin exposure. Note that in these experiments, the magnitude of desensitization depends strongly on the preceding calcium influx (Koplas et al., 1997) , and therefore it is important to select cells in which the calcium influxes in response to the conditioning pulse are similar, particularly in view of the fact (see Figure 7C and discussion below) that treatments such as upregulating AKAP79 by transfection or downregulating it by the use of siRNA modulate the maximum current amplitude. See legend to Figure 6D for further details.
Desensitization was largely abolished by removal of external Ca ( Figure 6D, bar 2) . Overexpression of AKAP79 strongly enhanced desensitization, while downregulation of endogenous AKAP79 by the use of siRNA substantially reduced it ( Figures  6C and 6D , bars 3 and 4). AKAP79 with either the PKA site or the PKC site deleted behaved similarly to WT AKAP79 ( Figure 6D , bars 5 and 6), showing that these kinases are not involved in desensitization when not activated by exogenous stimuli. Deletion of the calcineurin binding site, on the other hand, substantially reduced desensitization compared to that observed with expression of WT AKAP79 ( Figure 6D , last bar). In similar experiments on sensory neurons, inclusion of the 14 aa blocking peptide also reduced desensitization ( Figures 6E and 6F) .
These results implicate the calcineurin binding site of AKAP79 in the process of calcium-dependent desensitization of TRPV1. We note, however, that while removal of extracellular calcium almost completely abolished desensitization, removing the involvement of AKAP79, by downregulating AKAP79 with siRNA, by deleting the calcineurin binding site, or (in neurons) by preventing binding of AKAP79 to TRPV1 with the inhibitory peptide, reduced but did not abolish desensitization (see Figures 6C-6F) . A likely explanation is that another Ca-dependent mechanism of desensitization is also present, in addition to the calcineurin/ AKAP79 pathway. One possibility is that calmodulin may mediate calcium-dependent desensitization of TRPV1, either by activating CaM kinase (Jung et al., 2004; Novakova-Tousova et al., 2007) or by direct binding to a site in the intracellular N-terminal domain (Lishko et al., 2007) . (A) PGE 2 causes potent sensitization of inward current activated by a subsaturating pulse of capsaicin (100 nM, 5 s) in small DRG neurons. From top: control neurons; blocking peptide (200 mM) included in the patch-clamp pipette abolished sensitization; downregulation of AKAP150 with siRNA largely abolished sensitization; sensitization was rescued by cotransfection of AKAP79. Break in trace is 10 min period during which PGE 2 was constantly perfused without application of capsaicin. (B) Collected results of experiments similar to those in (A). PGE 2 caused sensitization (bar 2; *, p < 0.05 compared to control, n = 9). Inclusion of peptide abolished sensitization (bar 3; ##, p < 0.01 compared to bar 2, n = 13). SiRNA against AKAP150 largely abolished sensitization (bar 4; ##, p < 0.01 compared to bar 2, n = 19). Abolition of sensitization following transfection with siRNA could be rescued by cotransfection of AKAP79 (bar 5; **, p < 0.01 compared to control, n = 11). (C) Collected results of whole-cell voltage-clamp experiments on HEK293 cells transfected with TRPV1 and G q -coupled prostaglandin EP1 receptor (see example traces in Figure S2A ). PGE 2 (1 mM) caused potent sensitization (bar 2; **, p < 0.01 compared to control, n = 27). Overexpressing AKAP79 causes enhanced sensitization (bar 3; ##, p < 0.01 compared to bar 2, n = 5). Deleting the PKA binding site on AKAP79 has similar effect to WT AKAP79 (bar 4; ##, p < 0.01 compared to bar 2, n = 15). Deleting the PKC binding site abolishes sensitization (bar 5; #, p < 0.05 compared to bar 2, n = 20). Sensitization is abolished by downregulating expression of AKAP79 by the use of siRNA (bar 6; #, p < 0.05 compared to bar 2, n = 13). (D) Similar experiments in HEK293 cells transfected with the G s -coupled EP 4 receptor (see example traces in Figure S2B ). PGE 2 (1 mM) caused potent sensitization (bar 2; **, p < 0.01 compared to control, n = 13). Overexpressing AKAP79 does not further enhance sensitization (bar 3; ***, p < 0.001 compared to control, n = 6). Deleting the PKA binding site on AKAP79 abolishes sensitization (bar 4; #, p < 0.05 compared to bar 2, n = 8). Deleting the PKC binding site has no effect on sensitization (bar 5; *, p < 0.05 compared to control, n = 10). Sensitization is abolished by downregulating expression of AKAP79 by the use of siRNA (bar 6; ##, p < 0.01 compared to bar 2, n = 7).
AKAP79/150 Mediates Translocation of TRPV1 to the Membrane
In Figure 7 we investigated a possible effect of AKAP79/150 on trafficking of TRPV1 to the membrane. We first measured membrane expression of TRPV1 using biotinylation of surface membrane proteins ( Figures 7A and 7B ) or by expressing a functional TRPV1 in which an HA tag had been engineered into the third extracellular loop ( Figure 7H ). We also obtained an independent measure of surface membrane TRPV1 from the maximal membrane current elicited by a saturating dose of capsaicin ( Figures  7C and 7D) . With all three methods, overexpression of AKAP79 caused a robust increase in surface membrane TRPV1 expression. Conversely, downregulation of AKAP79 using siRNA reduced but did not eliminate membrane expression (Figures 7C  and 7D ). Deletion of either the PKC or the PKA binding site on AKAP79 largely negates the effect of AKAP79 in promoting translocation of TRPV1 to the membrane, while deletion of the PP2B binding site is without effect (Figures 7A-7D ). The PKA inhibitor H89 negates the effect of AKAP79 on trafficking of TRPV1 to the membrane ( Figure 7G , last lane). Thus, AKAP79-mediated phosphorylation of TRPV1 by both PKC and PKA is important in translocation of TRPV1 to the membrane.
We next sought to identify the residues on TRPV1 whose phosphorylation by PKC or PKA promotes trafficking to the membrane. Mutating S502 abolished the enhanced membrane expression caused by overexpression of AKAP79 ( Figure 7E ) or activation of PKA by forskolin ( Figure 7F ). By contrast, mutation of the S117 residue, which has been implicated in sensitization of TRPV1 by PKA (Bhave et al., 2002) , does not inhibit AKAP79-dependent membrane trafficking ( Figure 7G ). These experiments implicate phosphorylation of the S502 site as the main mechanism by which AKAP79 mediates translocation of TRPV1 to the surface membrane.
DISCUSSION
The experiments reported here show that inflammatory mediators acting via PKA or PKC depend completely on AKAP79/ 150 to mediate their effects on TRPV1 (see summary diagram in Figure 8 ). Two main mechanisms of sensitization have been identified in previous studies: an enhancement of gating of TRPV1 ion channels already in the membrane and an increase in trafficking of TRPV1 to the membrane.
In the first and best-studied mechanism, mediators such as PGE 2 or bradykinin activate either PKA or PKC3, which phosphorylate TRPV1 and increase the probability of gating of the channel by a wide range of activators. In the present study, we find that sensitization of channel gating depends on the ability of the relevant kinase to bind to AKAP79/150 and in turn on the ability of AKAP79/150 to bind to TRPV1. The observation that (A) AKAP79 does not mediate the sensitizing effects of NGF. From top: DRG neurons were exposed to near-saturating pulses of capsaicin (5 s, 1 mM) separated by a 10 min interval; application of NGF between pulses (100 ng/ml, 10 min) enhanced the inward current activated by capsaicin; the enhancement was not affected by inclusion of blocking peptide (200 mM) in the patch pipette. (B) Collected results of experiments similar to those in (A). *, p < 0.05; **, p < 0.01 compared to control (n = 12, 15, 13). (C) Activation of TRPV1 by a near-saturating dose of capsaicin (1 mM, 5 s) causes strong desensitization to a subsequent capsaicin application (top trace). Desensitization is enhanced by transfection of AKAP79 (middle trace) and is reduced but not abolished by downregulation of AKAP79 with siRNA (lower trace). Cells selected to have similar currents in response to conditioning application of capsaicin (see [D] ). (D) Collected results of experiments similar to those in (C). The magnitude of desensitization depends on the amplitude of the preceding inward current through TRPV1 (Koplas et al., 1997) , so to control for this potential source of variability data were only included from HEK293 cells with initial inward currents between 3.5 and 5.5 nA (i.e., current density between 100 and 200 pA/ pF). Desensitization is almost entirely Ca dependent (bar 2; ***, p < 0.001 compared to bar 1, n = 12). Desensitization is enhanced by transfection of AKAP79 (bar 3; *, p < 0.05 compared to bar 1, n = 9) and is reduced but not abolished by downregulating AKAP79 with siRNA (bar 4; *, p < 0.05 compared to bar 1, n = 8). Desensitization with PKA or PKC binding sites deleted is similar to WT AKAP (bars 5, 6; *, p < 0.05, **, p < 0.01 compared to bar 1, n = 7,5), but desensitization is reduced by deletion of PP2 binding site (bar 7; not significant compared to bar 1, n = 5). sensitization is completely abolished by disrupting either of these binding mechanisms, or by removal of AKAP79/150 using siRNA, implies that these two kinases must be preassembled in a signaling complex with TRPV1 in order to have any effect and thus that free PKA or PKC3 are unable to phosphorylate TRPV1 to any significant extent. The fact that inhibiting binding or removing AKAP79/150 inhibits sensitization adds further evidence to show that other possible mechanisms of sensitization, such as depletion of membrane PIP 2 following activation of PLC (Chuang et al., 2001; Prescott and Julius, 2003) , do not make any significant contribution to sensitization of TRPV1 under physiological conditions. AKAP79/150 is also involved in trafficking of TRPV1 to the surface membrane. Previous studies have shown that trafficking can be promoted by phosphorylation of TRPV1 either by Src (Zhang et al., 2005) or by PKC (Morenilla-Palao et al., 2004) . The first mechanism is insensitive to disruption of binding between AKAP79/150 and TRPV1, showing that Src does not depend on AKAP79/150 to assemble it into a signaling complex with TRPV1. The ability of PKC and PKA to enhance trafficking does, however, depend absolutely on the presence of functional AKAP79/150. We have shown that the main target of both kinases in promoting trafficking is S502, a residue which is also involved in the potentiation of channel gating (Numazaki et al., 2002; Bhave et al., 2003) .
We have concentrated mainly on the functional consequences of binding of AKAP79/150 to TRPV1, but we have also obtained biochemical evidence for interactions of AKAP79 with other members of the thermo-TRP family, in particular TRPV4, TRPM8, and TRPA1 (Figure 2) . The functional consequences of AKAP79 binding for the activation of these channels remain to be explored.
We have identified a 14 aa domain in the C-terminal domain of TRPV1 which mediates binding of AKAP79. Previous studies have found that AKAP79 binds diffusely to other proteins (Colledge et al., 2000) , so the identification of a small binding domain is something of a surprise. We did not find any obviously homologous binding domains on other thermo-TRPs, apart from an area of weak homology between residues 705 and 724 of the C-terminal domain of TRPA1, which suggests that AKAP79/ 150 binds to other thermo-TRP proteins at nonhomologous (Zhang et al., 2005) , is promoted by transfection with AKAP79. The effect of AKAP79 transfection is inhibited by deletion of the PKA or PKC binding sites on AKAP79, but is not affected by deletion of the PP2B (calcineurin) binding site. Lower image shows parallel experiment in which total TRPV1 was probed in total cell lysate to demonstrate constant loading of all lanes. (B) Mean band density obtained in three independent experiments. ***, p < 0.001 compared to bar 1; ###, p < 0.001 compared to bar 2. (C) Functional surface membrane expression of TRPV1 in HEK293 cells, measured in whole-cell voltage-clamp experiments in HEK293 cells from maximal current elicited by a saturating dose of capsaicin (10 mM applied for 1 s). Note that in these experiments, the very large currents can cause loss of voltage clamp, and experiments were therefore carried out in [Na] o = 30 mM (see Experimental Procedures). Maximum current amplitude is increased by transfection of AKAP79 and is inhibited by downregulation of AKAP79 using siRNA. (D) Mean results from experiments similar to (C). Maximum current density is reduced by downregulation of endogenous AKAP79 using siRNA (bar 2; *, p < 0.05 compared to bar 1; n = 20). AKAP79 transfection enhances maximum current density (bar 3; **, p < 0.01 compared to bar 1; n = 42) but the effect is negated by PKA or PKC site deletions, but not by PP2B site deletion. Bar 4, #, p < 0.05 compared to bar 3, n = 28; bar 5, #, p < 0.05 compared to bar 3; bar 4, not significantly different from bar 3, n = 24. (E) Enhancement of TRPV1 trafficking to the membrane by AKAP79 depends on the TRPV1 S502 site. Blots in (E)-(G) show surface membrane, obtained by biotinylation of intact HEK293 cells, and total TRPV1 as in (A). The enhanced TRPV1 surface expression caused by cotransfection with AKAP79 is abolished by the S502A mutation. Mean band densities from left, relative to major band at top left: 1.0, 1.44, 1.0, 1.03, n = 3. (F) Enhancement of TRPV1 trafficking to the membrane by PKA depends on the S502 site. Forskolin (100 mM, 30 min) applied as shown to enhance PKA activity. Mean band densities from left, relative to major band at top left: 1.0, 2.11, 1.0, 0.86, n = 3. (G) Mutation of the S117 site, which has also been shown to be a target for PKA (Bhave et al., 2002) , has no effect on enhancement of translocation of TRPV1 to the membrane caused by overexpression of AKAP79. Final lane shows that translocation caused by overexpression of AKA79 is partially PKA-dependent as it is inhibited by the PKA inhibitor H89 (1 mM for 30 min). Mean band densities from left, relative to major band at top left: 1.0, 1.66, 1.85, 1.01, n = 2. domains. A second possibility is that different intermediary proteins are involved in the binding to other thermo-TRPs, as was found for the binding of AKAP79/150 to the NMDA and AMPA receptors (Colledge et al., 2000) .
The dependence of sensitization of TRPV1 on AKAP79/150 raises the possibility that disrupting binding may reverse heat hyperalgesia in vivo. The binding site of AKAP79/150 to TRPV1 may therefore prove to be an attractive target for the development of novel analgesics.
EXPERIMENTAL PROCEDURES
Methods were as described previously (Zhang et al., 2005) with the following exceptions. Binding site deletions in AKAP79 for PKC, PKA, and PP2B were performed using overlapping PCR to remove regions identified by Hoshi et al. (2005) . AKAP79 and binding-site deletion mutants were GFP coupled so that successfully transfected cells could be identified in whole-cell patchclamp experiments. AKAP79 and AKAP150 were downregulated by using siRNA constructs (Hoshi et al., 2005) but cloned into the GFP-expressing vector GFP-pGSH1 (Gelantis Inc) so that transfected cells could be identified from their GFP fluorescence for patch-clamp studies. DRG neurons were transfected using the Amaxa Nucleofector according to the manufacturer's instructions. A peptide blocking the binding site between AKAP79 and TRPV1, and scrambled control peptide (see Figure 2) , were obtained from Sigma purified to 75% purity.
Whole-cell patch-clamp recordings were carried out at a holding potential of À60 mV and at room temperature, as described previously (Zhang et al., 2005) , except for experiments in which activation of TRPV1 was explored as a function of membrane voltage (Figure 3 ), when the holding potential was 0 mV. External solution for DRG neuron experiments contained 140 mM NaCl, 4 mM KCl, 10 mM HEPES, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM glucose (pH 7.4), while for experiments with HEK293 cells (with the exception of those shown in Figure 6 ), CaCl 2 was replaced with 5 mM EGTA to inhibit desensitization. For recording maximal current density ( Figure 7C ), calcium-free solution was used and [Na] o was reduced to 30 mM (substituted with choline chloride) in order to reduce the maximum membrane current amplitude, as described previously (Zhang et al., 2005) . For experiments using inhibitory peptide, DRG neurons were dialyzed with peptide-containing intracellular solution for 10 min before starting recording.
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Experimental Procedures are described in more detail in Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data include two figures and Supplemental Experimental Procedures and can be found with this article online at http://www.neuron. org/cgi/content/full/59/3/450/DC1/. The scaffolding protein AKAP79/150 binds to a 14 aa region in the C-terminal domain of the heat-activated ion channel TRPV1 (orange cylinder). The formation of this scaffolding complex aligns PKC3, the phosphatase calcineurin (PP2B) and PKA so as to control phosphorylation of key sites on TRPV1. The principal site involved in control of trafficking of TRPV1 to the membrane is S502. The tyrosine kinase Src can also promote trafficking to the membrane by phosphorylating Y200 (Zhang et al., 2005) but does so independently of AKAP79/150. TRPV1 has six ankyrin repeats in its N-terminal domain (Lishko et al., 2007) .
